CAR-T cells targeting CD19 for scleroderma, systemic

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trial registered. A trial in people is registered. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 12 Nov 2026: Trial registered, NCT07932262

The trials

NCT07932262: An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1

State
Not started
Phase
Phase 1 and Phase 2
People
36 planned
Started
Jan 2027
Primary completion
Jun 2028
Arms
Safety and feasibility
Results
None posted
  1. 12 Nov 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Trial registered

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.